

# David C Dale

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5815677/publications.pdf>

Version: 2024-02-01

179  
papers

12,928  
citations

36303  
51  
h-index

23533  
111  
g-index

181  
all docs

181  
docs citations

181  
times ranked

10239  
citing authors

#	ARTICLE	IF	CITATIONS
1	Heterozygous variants of <i>CLPB</i> are a cause of severe congenital neutropenia. <i>Blood</i> , 2022, 139, 779-791.	1.4	25
2	Neutropenia and infections: Neutrophil replacement through genetic engineering. <i>Journal of Leukocyte Biology</i> , 2022, , .	3.3	0
3	A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis. <i>Supportive Care in Cancer</i> , 2022, 30, 6135-6144.	2.2	3
4	Outcomes for patients with severe chronic neutropenia treated with granulocyte colony-stimulating factor. <i>Blood Advances</i> , 2022, 6, 3861-3869.	5.2	5
5	Mutant allele knockout with novel CRISPR nuclease promotes myelopoiesis in ELANE neutropenia. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 26, 119-131.	4.1	4
6	Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome. <i>Nature Communications</i> , 2021, 12, 1334.	12.8	103
7	Spectrum of Pathogenic Genetic Variants in a Large Cohort of North American Congenital and Cyclic Neutropenia Patients: A Report from the Severe Chronic Neutropenia International Registry. <i>Blood</i> , 2021, 138, 2059-2059.	1.4	0
8	Safe and Efficient Engraftment of CRISPR-Based ELANE Mono-Allelic Knocked out HSCs in Mice: Evidence for a Novel Treatment for ELANE Neutropenia. <i>Blood</i> , 2021, 138, 3122-3122.	1.4	0
9	Mavoxiafor, an Oral CXCR4 Antagonist, for Treatment of Patients with WHIM Syndrome: Results from the Long-Term Extension of the Open-Label Phase 2 Study. <i>Blood</i> , 2021, 138, 1121-1121.	1.4	1
10	The Experience of the Cooperation in Science and Technology European Network for Innovative Diagnosis and Treatment of Chronic Neutropenias (COST EuNet-INNOCHRON) Action and the Sweden Experience in the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Era. <i>Blood</i> , 2021, 138, 3125-3125.	1.4	0
11	Global Phase 3, Randomized, Placebo-Controlled Trial with Open-Label Extension Evaluating the Oral CXCR4 Antagonist Mavoxiafor in Patients with WHIM Syndrome (4WHIM): Trial Design and Enrollment. <i>Blood</i> , 2021, 138, 4310-4310.	1.4	2
12	Oral Administration of Mavoxiafor, a CXCR4 Antagonist, Increases Peripheral White Blood Cell Counts across Different Disease States. <i>Blood</i> , 2021, 138, 2186-2186.	1.4	1
13	CRISPR/Cas9-mediated <i>ELANE</i> knockout enables neutrophilic maturation of primary hematopoietic stem and progenitor cells and induced pluripotent stem cells of severe congenital neutropenia patients. <i>Haematologica</i> , 2020, 105, 598-609.	3.5	32
14	Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome. <i>Current Opinion in Hematology</i> , 2020, 27, 11-17.	2.5	7
15	Registries for study of nonmalignant hematological diseases: the example of the Severe Chronic Neutropenia International Registry. <i>Current Opinion in Hematology</i> , 2020, 27, 18-26.	2.5	9
16	Results of a phase 2 trial of an oral CXCR4 antagonist, mavoxiafor, for treatment of WHIM syndrome. <i>Blood</i> , 2020, 136, 2994-3003.	1.4	36
17	Neutropenia Is an Underrecognized Finding in Pediatric Primary Immunodeficiency Diseases: An Analysis of the United States Immunodeficiency Network Registry. <i>Journal of Pediatric Hematology/Oncology</i> , 2020, 42, e601-e605.	0.6	7
18	Distinct Genetic Pathways Define Leukemia Predisposition Versus Adaptive Clonal Hematopoiesis in Shwachman-Diamond Syndrome. <i>Blood</i> , 2020, 136, 35-36.	1.4	0

#	ARTICLE	IF	CITATIONS
19	CRISPR Mediated <i>ELANE</i> Single-Allele Knock-out Restores Proliferation and Myeloid Differentiation of Neutropenia Patient Derived BM HSCs. <i>Blood</i> , 2020, 136, 23-23.	1.4	1
20	Editorial. <i>Current Opinion in Hematology</i> , 2019, 26, 1-5.	2.5	0
21	Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor. <i>Current Opinion in Hematology</i> , 2019, 26, 16-21.	2.5	46
22	Neutropenia in Barth syndrome: characteristics, risks, and management. <i>Current Opinion in Hematology</i> , 2019, 26, 6-15.	2.5	35
23	CRISPR/Cas9 Mediated <i>ELANE</i> Knock-out Restores Survival and Granulocytic Differentiation of HL60 Cells Expressing Mutant Neutrophil Elastase: Is Neutrophil Elastase a Dispensable Granulocyte Protease?. <i>Blood</i> , 2019, 134, 435-435.	1.4	0
24	Family Studies of Whim Syndrome. <i>Blood</i> , 2019, 134, 215-215.	1.4	0
25	Severe Chronic Neutropenia in the Large Granular Lymphocyte Syndrome: Outcomes in Response to Granulocyte Colony Stimulating Factor (G-CSF) and Immunosuppressive Therapies. <i>Blood</i> , 2019, 134, 3589-3589.	1.4	0
26	Heterozygous Mutations of <i>Clpb</i> As a Newly Identified and Frequent Cause of Severe Congenital Neutropenia. <i>Blood</i> , 2019, 134, 433-433.	1.4	1
27	Editorial. <i>Current Opinion in Hematology</i> , 2018, 25, 1-2.	2.5	4
28	Analysis of Factors Associated With In-hospital Mortality in Lung Cancer Chemotherapy Patients With Neutropenia. <i>Clinical Lung Cancer</i> , 2018, 19, e163-e169.	2.6	24
29	Somatic mutations and clonal hematopoiesis in congenital neutropenia. <i>Blood</i> , 2018, 131, 408-416.	1.4	91
30	A systematic literature review of the efficacy, effectiveness, and safety of filgrastim. <i>Supportive Care in Cancer</i> , 2018, 26, 7-20.	2.2	51
31	Determination of Phase 3 Dose for X4P-001 in Patients with WHIM Syndrome. <i>Blood</i> , 2018, 132, 1102-1102.	1.4	0
32	Extended Genetic Testing in Severe Congenital Neutropenia May Identify Mutations That Inform Therapy. <i>Blood</i> , 2018, 132, 2401-2401.	1.4	4
33	CRISPR/Cas9 Knock-in HL60 Cells Closely Simulate Cellular and Functional Abnormalities of <i>ELANE</i> associated Neutropenia; Phenotype Rescue with MK-0339 Neutrophil Elastase Inhibitor. <i>Blood</i> , 2018, 132, 3683-3683.	1.4	0
34	A Novel Device Suitable for Home Monitoring of White Blood Cell and Neutrophil Counts. <i>Blood</i> , 2018, 132, 1103-1103.	1.4	0
35	Myelodysplasia, Leukemia, Lymphoid Malignancies, and Other Cancers in Patients with Severe Chronic Neutropenia. <i>Blood</i> , 2018, 132, 16-16.	1.4	2
36	Neutropenia Is an Under-Recognized Finding in Pediatric Primary Immunodeficiency Diseases: An Analysis of the United States Immunodeficiency Network Registry. <i>Blood</i> , 2018, 132, 3685-3685.	1.4	0

#	ARTICLE	IF	CITATIONS
37	How I manage children with neutropenia. British Journal of Haematology, 2017, 178, 351-363.	2.5	61
38	Severe congenital neutropenias. Nature Reviews Disease Primers, 2017, 3, 17032.	30.5	246
39	Elastase inhibitors as potential therapies for <i>ELANE</i>-associated neutropenia. Journal of Leukocyte Biology, 2017, 102, 1143-1151.	3.3	26
40	Editorial for myeloid biology 2017. Current Opinion in Hematology, 2017, 24, 1-2.	2.5	1
41	Long-Term Effects of G-CSF Therapy in Cyclic Neutropenia. New England Journal of Medicine, 2017, 377, 2290-2292.	27.0	35
42	An update on the diagnosis and treatment of chronic idiopathic neutropenia. Current Opinion in Hematology, 2017, 24, 46-53.	2.5	42
43	X4P-001: A Novel Molecularly-Targeted Oral Therapy for Whim Syndrome. Blood, 2017, 130, 995-995.	1.4	9
44	Long-Term Outcomes for G-CSF Treatment of Patients with Glycogen-Storage Disease Type Ib. Blood, 2017, 130, 996-996.	1.4	1
45	Association Between Absolute Neutrophil Count and Variation at <i>TCIRG1</i>: The NHLBI Exome Sequencing Project. Genetic Epidemiology, 2016, 40, 470-474.	1.3	11
46	How I diagnose and treat neutropenia. Current Opinion in Hematology, 2016, 23, 1-4.	2.5	42
47	Editorial: The mysteries of the spleen. Journal of Leukocyte Biology, 2016, 100, 249-251.	3.3	5
48	Peg-Filgrastim for the Treatment of Severe Chronic Neutropenia. Blood, 2016, 128, 1332-1332.	1.4	2
49	Termination and Frameshift Mutations in ELANE Are Associated with Adverse Outcomes in Patients with Severe Chronic Neutropenia. Blood, 2016, 128, 1326-1326.	1.4	2
50	Germline and Somatic Genetic Characterization of Shwachman-Diamond Syndrome. Blood, 2016, 128, 2681-2681.	1.4	0
51	Mutation Burden in Hematopoietic Stem Cells Is Not Increased in Congenital Neutropenia. Blood, 2016, 128, 405-405.	1.4	2
52	TCIRG1 Mutations As a Cause for Chronic Neutropenia. Blood, 2016, 128, 2511-2511.	1.4	0
53	The Effects of the Neutrophil Elastase Inhibitors MK0339 and Sivelestat on the Survival, Proliferation and Maturation of iPSC and HL60 Cells Expressing Mutant Neutrophil Elastase. Blood, 2016, 128, 406-406.	1.4	0
54	Assessing patientsâ€™ risk of febrile neutropenia: is there a correlation between physicianâ€™s assessed risk and modelâ€™s predicted risk?. Cancer Medicine, 2015, 4, 1153-1160.	2.8	27

#	ARTICLE	IF	CITATIONS
55	The diversity of mutations and clinical outcomes for ELANE-associated neutropenia. Current Opinion in Hematology, 2015, 22, 3-11.	2.5	123
56	Understanding, Treating and Avoiding Hematological Disease: Better Medicine Through Mathematics?. Bulletin of Mathematical Biology, 2015, 77, 739-757.	1.9	30
57	The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort study. SpringerPlus, 2015, 4, 396.	1.2	16
58	The effects of the CXCR2 antagonist, MK-7123, on bone marrow functions in healthy subjects. Cytokine, 2015, 72, 197-203.	3.2	13
59	Use of Granulocyte Colony-Stimulating Factor During Pregnancy in Women With Chronic Neutropenia. Obstetrics and Gynecology, 2015, 125, 197-203.	2.4	38
60	Intersections of hematology, immunology, dermatology and infectious diseases. Current Opinion in Hematology, 2015, 22, 1-2.	2.5	2
61	Cost of Hospitalization in Patients with Cancer and Febrile Neutropenia and Impact of Comorbid Conditions. Blood, 2015, 126, 2089-2089.	1.4	10
62	Is There a Role for Anti-Neutrophil Antibody Testing in Predicting Spontaneous Resolution of Neutropenia in Young Children. Blood, 2015, 126, 2211-2211.	1.4	13
63	The North American Shwachman-Diamond Syndrome Registry: Genetically Undefined Shwachman-Diamond Syndrome. Blood, 2015, 126, 3614-3614.	1.4	0
64	Barth Syndrome: An Under-Recognized Cause of Chronic Neutropenia. Blood, 2015, 126, 2195-2195.	1.4	0
65	Application of Spectral Density/Periodogram Analysis to Serial Neutrophil Counts to Diagnose Cyclic Neutropenia. Blood, 2015, 126, 4608-4608.	1.4	0
66	Long Term Outcomes for Patients with Cyclic Neutropenia Treated with Granulocyte Colony-Stimulating Factor (G-CSF). Blood, 2015, 126, 996-996.	1.4	1
67	Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics. Genetics in Medicine, 2014, 16, e1-e29.	2.4	318
68	<i>TCIRG1</i>-Associated Congenital Neutropenia. Human Mutation, 2014, 35, 824-827.	2.5	35
69	Variable Clinical Presentation of Shwachmanâ€Diamond Syndrome: Update from the North American Shwachmanâ€Diamond Syndrome Registry. Journal of Pediatrics, 2014, 164, 866-870.	1.8	121
70	Cancer Chemotherapy Treatment Patterns and Febrile Neutropenia in the US Veterans Health Administration. Value in Health, 2014, 17, 739-743.	0.3	5
71	Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis. Blood, 2014, 123, 2229-2237.	1.4	135
72	Evaluation and Management of Patients With Isolated Neutropenia. Seminars in Hematology, 2013, 50, 198-206.	3.4	167

#	ARTICLE	IF	CITATIONS
73	Myelosuppression. , 2013, , 187-205.		2
74	Colony-Stimulating Factors for Prevention and Treatment of Neutropenia and Infectious Diseases. , 2013, , 399-417.		1
75	Neutropenia In Glycogen Storage Disease 1b (GSD1b). Blood, 2013, 122, 2265-2265.	1.4	2
76	Cooperativity Of RUNX1 and CSF3R Mutations In The Development Of Leukemia In Severe Congenital Neutropenia: A Unique Pathway In Myeloid Leukemogenesis. Blood, 2013, 122, 444-444.	1.4	1
77	TCIRG1 Associated Congenital Neutropenia. Blood, 2013, 122, 440-440.	1.4	0
78	Barth Syndrome and Neutropenia. Blood, 2013, 122, 3465-3465.	1.4	0
79	Guidelines for pediatric management of severe chronic neutropenia. American Journal of Hematology, 2012, 87, 133-133.	4.1	10
80	Clinical Outcomes for Patients with Severe Chronic Neutropenia Due to Mutations in the Gene for Neutrophil Elastase, ELANE. Blood, 2012, 120, 3275-3275.	1.4	1
81	rHuG-CSF for the Treatment of Severe Chronic Neutropenia. , 2012, , 279-291.		0
82	The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome. Blood, 2011, 118, 4963-4966.	1.4	101
83	Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer, 2011, 117, 1917-1927.	4.1	195
84	Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy. British Journal of Haematology, 2010, 150, 196-199.	2.5	211
85	Cyclic and Chronic Neutropenia. Cancer Treatment and Research, 2010, 157, 97-108.	0.5	64
86	Outcomes of Pregnancies for Women with Severe Chronic Neutropenia with or without G-CSF Treatment.. Blood, 2010, 116, 1490-1490.	1.4	5
87	Neutrophil Elastase Mutations and the Risk of Leukemia In Patients with Cyclic and Congenital Neutropenia.. Blood, 2010, 116, 3786-3786.	1.4	2
88	Barth Syndrome and Severe Chronic Neutropenia.. Blood, 2010, 116, 3787-3787.	1.4	1
89	The Many Causes of Severe Congenital Neutropenia. New England Journal of Medicine, 2009, 360, 3-5.	27.0	75
90	Prevalence of mutations in <i>ELANE</i> , <i>GFI1</i> , <i>HAX1</i> , <i>SBDS</i> , <i>WAS</i> and <i>G6PC3</i> in patients with severe congenital neutropenia. British Journal of Haematology, 2009, 147, 535-542.	2.5	147

#	ARTICLE	IF	CITATIONS
91	Genetic and molecular diagnosis of severe congenital neutropenia. Current Opinion in Hematology, 2009, 16, 9-13.	2.5	41
92	Granulocyte transfusion therapy: a new era?. Current Opinion in Hematology, 2009, 16, 1-2.	2.5	15
93	Advances in the treatment of neutropenia. Current Opinion in Supportive and Palliative Care, 2009, 3, 207-212.	1.3	24
94	Neutrophil Biology and the Next Generation of Myeloid Growth Factors. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 92-98.	4.9	6
95	The phagocytes: neutrophils and monocytes. Blood, 2008, 112, 935-945.	1.4	558
96	Risk and Timing of Neutropenic Events in Adult Cancer Patients Receiving Chemotherapy: The Results of a Prospective Nationwide Study of Oncology Practice. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, 109-118.	4.9	192
97	Achieving a High-Performance Health Care System: Policies and Positions of the American College of Physicians. Endocrine Practice, 2008, 14, 502-504.	2.1	1
98	Neutropenia and Its Complications. Translational Medicine Series, 2008, , 1-19.	0.0	0
99	Spontaneous Recovery and Normalization of Blood Neutrophil Counts in Young Children with Severe Chronic Neutropenia. Blood, 2008, 112, 3560-3560.	1.4	0
100	What is WHIM syndrome?. Blood, 2007, 109, 4-4.	1.4	0
101	Therapeutic Use of Granulocyte Colony-Stimulating Factors for Established Febrile Neutropenia. Pharmacoeconomics, 2007, 25, 343-351.	3.3	26
102	Impact of Primary Prophylaxis With Granulocyte Colony-Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy: A Systematic Review. Journal of Clinical Oncology, 2007, 25, 3158-3167.	1.6	639
103	Neutrophil elastase mutations and risk of leukaemia in severe congenital neutropenia. British Journal of Haematology, 2007, 140, 071120230220002-???	2.5	77
104	A Conditional Risk Model for Chemotherapy-Induced Anemia (CIA) in Cancer Patients.. Blood, 2007, 110, 372-372.	1.4	2
105	Myeloid Growth Factors Guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 2007, 5, 188.	4.9	60
106	Cyclic Neutropenia Is Not Associated with Transformation to MDS and AML.. Blood, 2007, 110, 3306-3306.	1.4	0
107	Predictors of Transformation to Myelodysplasia/Acute Myelogenous Leukemia (MDS/AML) in Severe Congenital Neutropenia (SCN).. Blood, 2007, 110, 3307-3307.	1.4	0
108	Recertification in internal medicine - the American experience. Annals of the Academy of Medicine, Singapore, 2007, 36, 894-7.	0.4	2

#	ARTICLE	IF	CITATIONS
109	The Severe Chronic Neutropenia International Registry: 10-Year Follow-up Report. Supportive Cancer Therapy, 2006, 3, 220-231.	0.3	135
110	Severe Congenital Neutropenia. Seminars in Hematology, 2006, 43, 189-195.	3.4	172
111	Strong evidence for autosomal dominant inheritance of severe congenital neutropenia associated with ELA2 Mutations. Journal of Pediatrics, 2006, 148, 633-636.	1.8	46
112	The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood, 2006, 107, 4628-4635.	1.4	394
113	Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Research and Treatment, 2006, 100, 255-262.	2.5	129
114	Epoetin alfa increases hemoglobin levels and improves quality of life in anemic geriatric cancer patients receiving chemotherapy. Supportive Care in Cancer, 2006, 14, 1184-1194.	2.2	11
115	Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer, 2006, 106, 2258-2266.	4.1	983
116	Genotype-Phenotype Associations in Patients with Severe Congenital Neutropenia.. Blood, 2006, 108, 502-502.	1.4	0
117	Mutations of the ELA2 Gene Found in Patients with Severe Congenital Neutropenia Induce the Unfolded Protein Response and Cellular Apoptosis.. Blood, 2006, 108, 499-499.	1.4	0
118	Prospective Validation of a Predictive Model for Early Anemia in Patients Receiving Cancer Chemotherapy.. Blood, 2006, 108, 460-460.	1.4	2
119	Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion, 2005, 45, 295-300.	1.6	213
120	Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. Journal of Experimental Medicine, 2005, 201, 1307-1318.	8.5	1,003
121	Mutant CXCR4 Identified in Neutropenic Patients with Myelokathexis Impairs Survival of Human Myeloid Cells.. Blood, 2005, 106, 3071-3071.	1.4	0
122	A Prospective Risk Model for Neutropenic Complications in Patients with Malignant Lymphoma.. Blood, 2005, 106, 3328-3328.	1.4	0
123	Dose Intensity and Hematologic Toxicity in Older Cancer Patients Receiving Systemic Chemotherapy.. Blood, 2005, 106, 3124-3124.	1.4	0
124	A Risk Model for Chemotherapy-Induced Anemia (CIA) in Cancer Patients.. Blood, 2005, 106, 754-754.	1.4	0
125	Incidence and Predictors of Low Chemotherapy Dose-Intensity in Aggressive Non-Hodgkin's Lymphoma: A Nationwide Study. Journal of Clinical Oncology, 2004, 22, 4302-4311.	1.6	285
126	Leukocytosis and Mobilization of CD34+ Hematopoietic Progenitor Cells by AMD3100, a CXCR4 Antagonist. Supportive Cancer Therapy, 2004, 1, 165-172.	0.3	91



#	ARTICLE	IF	CITATIONS
127	Kostmann syndrome: severe congenital neutropenia associated with defective expression of Bcl-2, constitutive mitochondrial release of cytochrome c, and excessive apoptosis of myeloid progenitor cells. Blood, 2004, 103, 3355-3361.	1.4	78
128	Neutrophil elastase and neutropenia. Blood, 2004, 103, 3993-3994.	1.4	1
129	First Cycle Risk of Severe and Febrile Neutropenia in Cancer Patients Receiving Systemic Chemotherapy: Results from a Prospective Nationwide Study.. Blood, 2004, 104, 2210-2210.	1.4	14
130	Reduced Relative Dose Intensity (RDI) in Patients with Aggressive Non-Hodgkin's Lymphoma (NHL).. Blood, 2004, 104, 3314-3314.	1.4	2
131	Neutropenia and the Problem of Fever and Infection in Patients With Cancer. , 2004, , 219-233.		1
132	Predicting the Risk of Neutropenic Complications and Reduced Dose Intensity in Patients with Malignant Lymphoma: Results from a Prospective Study.. Blood, 2004, 104, 4599-4599.	1.4	0
133	Validation of a Risk Model for Hospitalized Adult Cancer Patients with Febrile Neutropenia.. Blood, 2004, 104, 89-89.	1.4	3
134	Molecular basis and therapy of disorders associated with chronic neutropenia. Current Allergy and Asthma Reports, 2003, 3, 385-388.	5.3	13
135	Cellular and molecular abnormalities in severe congenital neutropenia predisposing to leukemia. Experimental Hematology, 2003, 31, 372-381.	0.4	57
136	Current management of chemotherapy-induced neutropenia: the role of colony-stimulating factors. Seminars in Oncology, 2003, 30, 3-9.	2.2	31
137	Severe chronic neutropenia: Treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. American Journal of Hematology, 2003, 72, 82-93.	4.1	331
138	Myelotoxicity and Dose Intensity of Chemotherapy: Reporting Practices From Randomized Clinical Trials. Journal of the National Comprehensive Cancer Network: JNCCN, 2003, 1, 440-454.	4.9	82
139	Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood, 2003, 102, 2728-2730.	1.4	684
140	Poor prognosis in elderly patients with cancer: the role of bias and undertreatment. The Journal of Supportive Oncology, 2003, 1, 11-7.	2.3	27
141	Optimizing the management of chemotherapy-induced neutropenia. Clinical Advances in Hematology and Oncology, 2003, 1, 679-84.	0.3	8
142	Colony-Stimulating Factors for the Management of Neutropenia in Cancer Patients. Drugs, 2002, 62, 1-15.	10.9	150
143	Cyclic neutropenia. Seminars in Hematology, 2002, 39, 89-94.	3.4	145
144	Introduction: Severe chronic neutropenia. Seminars in Hematology, 2002, 39, 73-74.	3.4	6

#	ARTICLE	IF	CITATIONS
145	Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors. Transfusion, 2002, 42, 1414-1421.	1.6	121
146	Therapeutic Use of Cytokines to Modulate Phagocyte Function for the Treatment of Infectious Diseases: Current Status of Granulocyte Colony-Stimulating Factor, Granulocyte-Macrophage Colony-Stimulating Factor, Macrophage Colony-Stimulating Factor, and Interferon- $\gamma$ . Journal of Infectious Diseases, 2002, 185, 1490-1501.	4.0	150
147	Alpha Omega Alpha: encouraging excellence in medicine for more than a century. The Pharos of Alpha Omega Alpha-honor Medical Society Alpha Omega Alpha, 2002, 65, 4-21.	0.1	1
148	Impaired survival of bone marrow hematopoietic progenitor cells in cyclic neutropenia. Blood, 2001, 97, 147-153.	1.4	82
149	Mutations in the neutrophil elastase gene in cyclic and congenital neutropenia. Current Opinion in Immunology, 2001, 13, 535-538.	5.5	42
150	Clinical Implications of Mutations of Neutrophil Elastase in Congenital and Cyclic Neutropenia. The American Journal of Pediatric Hematology/oncology, 2001, 23, 208-210.	1.3	15
151	Modeling Complex Neutrophil Dynamics in the Grey Collie. Journal of Theoretical Biology, 2000, 204, 505-519.	1.7	63
152	Myelokathexis, a congenital disorder of severe neutropenia characterized by accelerated apoptosis and defective expression of bcl-x in neutrophil precursors. Blood, 2000, 95, 320-327.	1.4	110
153	Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia. Blood, 2000, 96, 2317-2322.	1.4	529
154	Inhibition of in Vivo Neutrophil Transmigration by a Novel Humanized Anti-CD11/CD18 Monoclonal Antibody. Cytokines, Cellular & Molecular Therapy, 2000, 6, 121-126.	0.3	8
155	Use of G-CSF for granulocyte transfusion therapy. Cytokines, Cellular & Molecular Therapy, 2000, 6, 89-95.	0.3	8
156	Mutations in ELA2, encoding neutrophil elastase, define a 21-day biological clock in cyclic haematopoiesis. Nature Genetics, 1999, 23, 433-436.	21.4	444
157	Occurrence of periodic oscillations in the differential blood counts of congenital, idiopathic, and cyclical neutropenic patients before and during treatment with G-CSF. Experimental Hematology, 1999, 27, 401-409.	0.4	81
158	Hematopoietic dynamics in grey collies. Experimental Hematology, 1999, 27, 1139-1148.	0.4	42
159	Neutrophils: Function and Role in Sepsis Syndrome. Sepsis, 1998, 2, 107-117.	0.5	7
160	Effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) on neutrophil kinetics and function in normal human volunteers. , 1998, 57, 7-15.		68
161	Cyclical Neutropenia and Other Periodic Hematological Disorders: A Review of Mechanisms and Mathematical Models. Blood, 1998, 92, 2629-2640.	1.4	209
162	In Vivo Effects of Recombinant Human Granulocyte Colony-Stimulating Factor on Neutrophil Oxidative Functions in Normal Human Volunteers. Journal of Infectious Diseases, 1997, 175, 1184-1192.	4.0	44

#	ARTICLE	IF	CITATIONS
163	Chronic Thrombocytopenia Is Induced in Dogs by Development of Cross-Reacting Antibodies to the Mpl Ligand. Blood, 1997, 90, 3456-3461.	1.4	26
164	RENEWED INTEREST IN GRANULOCYTE TRANSFUSION THERAPY. British Journal of Haematology, 1997, 98, 497-501.	2.5	48
165	Aging and Haemopoiesis. Drugs and Aging, 1996, 9, 37-47.	2.7	54
166	Genetics, phenotype, and natural history of autosomal dominant cyclic hematopoiesis. , 1996, 66, 413-422.		83
167	Current Approach to the Management of Neutropenia. Journal of Intensive Care Medicine, 1995, 10, 283-293.	2.8	15
168	Hematopoietic growth factors for the treatment of severe chronic neutropenia. Stem Cells, 1995, 13, 94-100.	3.2	26
169	Long-term safety of treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) in patients with severe congenital neutropenias. British Journal of Haematology, 1994, 88, 723-730.	2.5	195
170	Aging and Marrow Neutrophil Reserves. Journal of the American Geriatrics Society, 1994, 42, 77-81.	2.6	50
171	Cyclic Neutropenia: Natural History and Effects of Long-Term Treatment with Recombinant Human Granulocyte Colony-Stimulating Factor. Cancer Investigation, 1993, 11, 219-223.	1.3	27
172	Treatment of Cyclic Neutropenia with Granulocyte Colony-Stimulating Factor. New England Journal of Medicine, 1989, 320, 1306-1311.	27.0	347
173	Mechanism of canine cyclic hematopoiesis: The role of prostaglandin E in feedback regulation. American Journal of Hematology, 1983, 14, 27-36.	4.1	2
174	Human Cyclic Neutropenia: Clinical Review and Long-Term Follow-up of Patients. Medicine (United Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.0	148
175	Chronic Neutropenia. Medicine (United States), 1979, 58, 128-144.	1.0	155
176	Effect of prophylactic colchicine therapy on leukocyte function in patients with familial mediterranean fever. Arthritis and Rheumatism, 1976, 19, 618-622.	6.7	108
177	Human Cyclic Neutropenia: Urinary Colony-stimulating Factor and Erythropoietin Levels. Blood, 1974, 44, 257-262.	1.4	28
178	Hematopoietic Growth Factors (Cytokines). , 0, , 498-507.		0
179	Neutropenia. , 0, , 215-220.		1